Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 4)

Link copied
Case Copied 21 min read

FEDERAL COURT OF AUSTRALIA

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 4) [2020] FCA 1776

File number: NSD 656 of 2017
Judgment of: NICHOLAS J
Date of judgment: 11 December 2020
Catchwords: PATENTS – application to amend statement of claim to reformulate claim for additional damages under s 122(1A) of the Patents Act 1990 (Cth) – whether matters proposed to be relied upon by applicant reasonably capable of warranting award of additional damages – where no allegation made that respondents knew or had reason to believe that they were infringing patent – relevance of benefits alleged to have been obtained by respondents because of their alleged infringements
Legislation:

Copyright Act 1968 (Cth)

Copyright Amendment (Parallel Importation) Act 2003 (Cth) s 115(4)

Federal Court of Australia Act 1976 (Cth) s 37M

Intellectual Property Laws Amendment Act 2006 (Cth)

Patents Act 1990 (Cth) ss 105, 122(1), 122(1A)

Therapeutic Goods Act 1989 (Cth) s 26B

Copyright Act 1956 (UK) s 17(3)

Cases cited:

Aon Risk Services Australia Ltd v Australian National University (2009) 239 CLR 175

Aristocrat Technologies Australia Pty Ltd v D.A.P. Services (Kempsey) Pty Ltd (2007) 157 FCR 564

Cement Australia Pty Ltd v Australian Competition and Consumer Commission (2010) 187 FCR 261

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 2) [2019] FCA 154; (2019) 139 IPR 424

Ravenscroft v Herbert [1980] RPC 193

Tamaya Resources Ltd (In Liq) v Deloitte Touche Tohmatsu (A Firm) (2016) 332 ALR 199

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 37
Date of hearing: 18 November 2020
Counsel for the Applicant/Cross-Respondent: Mr D Shavin QC with Ms L Thomas
Solicitor for the Applicant/Cross-Respondent: DLA Piper Australia
Counsel for the Respondents/Cross-Claimants: Mr N Murray SC with Mr B Mee
Solicitor for the Respondents/Cross-Claimants: Herbert Smith Freehills

ORDERS

NSD 656 of 2017
BETWEEN:

NEURIM PHARMACEUTICALS (1991) LTD

Applicant

AND:

GENERIC PARTNERS PTY LTD (ACN 132 833 777)

First Respondent

APOTEX PTY LTD ACN (096 916 148)

Second Respondent

AND BETWEEN:

APOTEX PTY LTD (ACN 096 916 148)

Cross-Claimant

AND:

NEURIM PHARMACEUTICALS (1991) LTD

Cross-Respondent

AND BETWEEN:

GENERIC PARTNERS PTY LTD (ACN 132 833 777)

Cross-Claimant

AND:

NEURIM PHARMACEUTICALS (1991) LTD

Cross-Respondent

ORDER MADE BY:

NICHOLAS J

DATE OF ORDER:

11 DECEMBER 2020

THE COURT ORDERS THAT:

1.Within 7 days the applicant is to file and serve a draft further amended statement of claim that deletes paragraph 45 and includes a new paragraph 45A which confines the claim for additional damages to one based on benefits alleged to have accrued to the respondents because of the respondents’ alleged patent infringements and which otherwise conforms with the rulings contained in the reasons for judgment published today.

2.All questions concerning the costs of the applicant’s application for leave to amend the amended statement of claim be reserved.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

NICHOLAS J:

  1. Before…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCA 1776
Decision Date

CaseChat Overview and Summary

Neurim Pharmaceuticals (1991) Ltd sought leave to amend its statement of claim in proceedings against Generic Partners Pty Ltd, to include a claim for additional damages under section 122(1A) of the Patents Act 1990 (Cth). The applicants sought to amend their statement of claim to include a new paragraph 45A, which would confine the claim for additional damages to one based on the benefits alleged to have accrued to the respondents because of their alleged patent infringements. The respondents opposed the application, arguing that the proposed new paragraph 45A did not comply with the requirements of section 122(1A) of the Act.

The court was required to determine whether the matters proposed to be relied upon by Neurim reasonably warranted an award of additional damages. The court considered the four elements of section 122(1A) of the Act, which are: the flagrancy of the infringement; the need to deter similar infringements of patents; the conduct of the party that infringed the patent after the act constituting the infringement or after they were informed that they had allegedly infringed the patent; and any benefit shown to have accrued to that party because of the infringement. The court also considered the relevance of benefits alleged to have been obtained by the respondents because of their alleged infringements, and whether Neurim had made any allegation that the respondents knew or had reason to believe that they were infringing the patent.

The court found that the matters relied on by Neurim in support of its claim for additional damages as pleaded and particularised could be summarised as follows: (1) ARTG Registration – the respondents launched their melatonin products into the Australian market on the basis of an ARTG registration that mirrors Neurim’s ARTG registration for Circadian, for a use that infringes the patent, and that permits supply of products which may be prescribed by a medical practitioner for the treatment of the registered indication or “off label” indications; (2) Timing of Product Launch – the respondents launched their product after the affidavit evidence was filed, and after the trial dates had been vacated due to circumstances outside the parties’ control; (3) Stripping of Benefits – the respondents have made substantial benefits from their infringements, which have “been enabled by, but extend beyond, their infringing conduct”, including the benefits flowing to the respondents and their related entities due to “bundling deals” or other discounting arrangements, the benefit of the “first mover advantage” arising out of the respondents’ entry into the market before expiry of the patent, and by entering into non-arms length transactions and financial arrangements; and (4) Deterrence – an award of additional damages is necessary to deter similar infringements of the patents by the respondents and other persons. The court found that the proposed new paragraph 45A did not comply with the requirements of section 122(1A) of the Act, as it did not sufficiently particularise the matters relied on by Neurim in support of its claim for additional damages. The court ordered that within 7 days the applicant was to file and serve a draft further amended statement of claim that deleted paragraph 45 and included a new paragraph 45A which confined the claim for additional damages to one based on benefits alleged to have accrued to the respondents because of the respondents’ alleged patent infringements and which otherwise conformed with the rulings contained in the reasons for judgment published that day. All questions concerning the costs of the applicant’s application for leave to amend the amended statement of claim were to be reserved.

Orders

Orders of the court

1. Within 7 days the applicant is to file and serve a draft further amended statement of claim that deletes paragraph 45 and includes a new paragraph 45A which confines the claim for additional damages to one based on benefits alleged to have accrued to the respondents because of the respondents’ alleged patent infringements and which otherwise conforms with the rulings contained in the reasons for judgment published today.

2. All questions concerning the costs of the applicant’s application for leave to amend the amended statement of claim be reserved.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

The matters relied on by Neurim in support of its claim for additional damages as pleaded and particularised can be summarised as follows:(1)ARTG Registration – The respondents launched their melatonin products into the Australian market on the basis of an ARTG registration:(a)that mirrors Neurim’s ARTG registration for Circadian; (b)for a use that infringes the patent; (c)that permits supply of products which may be prescribed by a medical practitioner for the treatment of the registered indication or “off label” indications. (2)Timing of Product Launch – The respondents launched their product after the affidavit evidence was filed, and after the trial dates had been vacated due to circumstances outside the parties’ control. (3)Stripping of Benefits – The respondents have made substantial benefits from their infringements, which have “been enabled by, but extend beyond, their infringing conduct” including:(a)the benefits flowing to the respondents and their related entities due to “bundling deals” or other discounting arrangements; (b)the benefit of the “first mover advantage” arising out of the respondents’ entry into the market before expiry of the patent; and(c)by entering into non-arms length transactions and financial arrangements.(4)Deterrence – An award of additional damages is necessary to deter similar infringements of the patents by the respondents and other persons. Section 122(1) and s 122(1A) of the Act provide:(1)The relief which a court may grant for infringement of a patent includes an injunction (subject to such terms, if any, as the court thinks fit) and, at the option of the plaintiff, either damages or an account of profits.(1A)A court may include an additional amount in an assessment of damages for an infringement of a patent, if the court considers it appropriate to do so having regard to:(a) the flagrancy of the infringement; and(b) the need to deter similar infringements of patents; and(c) the conduct of the party that infringed the patent that occurred:(i) after the act constituting the infringement; or(ii)after that party was informed that it had allegedly infringed the patent; and(d)any benefit shown to have accrued to that party because of the infringement; and(e) all other relevant matters. Section 122(1A) of the Act was introduced by the Intellectual Property Laws Amendment Act 2006 (Cth), Schedule 5. However, well before s 122(1A) was introduced, additional damages was a remedy available under the Copyright Act 1968 (Cth) (“the Copyright Act”). Most of the relevant case law relates to the availability of additional damages for copyright infringement. The Copyright Act originally provided in s 115(4):(4) Where, in an action under this section:(a) an infringement of copyright is established; and(b) the court is satisfied that it is proper to do so, having regard to:(i) the flagrancy of the infringement;(ii)any benefit shown to have accrued to the defendant by reason of the infringement; and(iii) all other relevant matters;the court may, in assessing damages for the infringement, award such additional damages as it considers appropriate in the circumstances.